Day: September 19, 2024

Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function Wegovy® (semaglutide 2.4 mg) is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise function in people with obesity-related heart failure with preserved ejection fraction (HFpEF). The positive opinion is based on results from the STEP HFpEF and STEP HFpEF-DM trials, which showed that Wegovy® is an effective therapy compared to placebo for people with obesity-related HFpEF.1,2 Bagsværd, Denmark, 19 September 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an...

Idaho Copper Corporation MineSense XRF shovel-based sensors Idaho Copper Corporation MineSense XRF shovel-based sensors Boise, Idaho, Sept. 19, 2024 (GLOBE NEWSWIRE) — Idaho Copper Corp. (OTC Pink: COPR) is pleased to announce that it has received initial results from scanning and amenability testwork performed using MineSense XRF scanning technology from representative samples of the three main geological zones at the CuMo Idaho copper-molybdenum-silver deposit. These samples were tested by MineSense at its Vancouver, BC, Canada facility, and involved a series of simulations: First, run of mine ore samples from each zone were repeatedly sent (ten times) through the MineSense XRF sensor ATM system, which replicates a mining shovel bucket Next, the ore was crushed to

WILMINGTON, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) — UniFirst Corporation (NYSE: UNF), a North American leader in the supply and servicing of uniform and workwear programs, facility service products, and first aid and safety supplies, is pleased to announce the appointment of Kelly Rooney as Chief Operating Officer (COO), effective September 30, 2024. Rooney has extensive knowledge and experience in large-scale B2B route-based operations. Over her twenty-five plus year career, she has held operational and leadership roles of increasing responsibility. Her most recent position was as the Chief Human Resources Officer at Waste Management, a $20 billion public company. Rooney is returning to her roots and will oversee UniFirst’s day-to-day operations, focusing on driving growth, enhancing customer service excellence, and executing...

Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesis SOLANA BEACH, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, reaffirms its commitment to improving the lives of patients suffering from diabetic gastroparesis in light of the recent decision by the U.S. Food and Drug Administration (FDA) to not approve Vanda Pharmaceuticals new drug application (NDA) for Tradipitant, an oral drug candidate for the treatment of symptoms in gastroparesis. Patients suffering from all forms of gastroparesis need additional agents to help treat this difficult disease, and we believe patients will be disappointed given...

GRANTS, NEW MEXICO, Sept. 19, 2024 (GLOBE NEWSWIRE) — Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”), today announced that trading of its shares have been suspended from the Nasdaq Stock Exchange (“Nasdaq”) after Nasdaq cancelled the scheduled September 26, 2024 delist appeal hearing. While this development represents a change in the Company’s public trading status, Bright Green remains committed to pursuing its strategic goals and delivering value to its shareholders. The Company filed its Proxy Statement and will proceed with its scheduled annual meeting on November 15, 2024, during which shareholders will discuss key issues, including the potential for a reverse stock split aimed at enhancing shareholder value and positioning the Company for future success. In addition to these efforts, the Company...

GRAND CAYMAN, Cayman Islands, Sept. 19, 2024 (GLOBE NEWSWIRE) — SRIVARU Holding Limited (Nasdaq: SVMH, SVMHW) (“SRIVARU” or the “Company”), a leading innovator in the electric motorcycle market, today announced that it has received a favorable decision from the Nasdaq Hearings Panel (the “Panel”). The Panel’s decision grants the Company’s request for continued listing on Nasdaq, which we believe will provide SRIVARU the necessary time to implement its plan to regain compliance with Nasdaq’s listing requirements. Following the Company’s hearing on September 5, 2024, the Panel has stipulated specific conditions for continued listing. SRIVARU must fulfill the below requirements by November 14, 2024: Submitting a public filing and financial statements that confirm the Company meets Nasdaq’s shareholder...

Regulated Information Issy-les-Moulineaux, September 19, 2024 DISCLOSURE OF TRANSACTIONS IN OWN SHARES CARRIED OUT FROM SEPTEMBER 16 TO SEPTEMBER 17, 2024 Sodexo purchased treasury shares, outside of its liquidity contract, within the framework of its share buyback program as authorized by the Shareholders’ Meeting held on December 15, 2023. These shares have been acquired to honor obligations related to free shares award plans. Information on these transactions are the following: Trading date LEI ISIN Volume(in number of shares) Weighted average purchase price (in euros) Market             16/09/2024 969500AGKR3PRJG4WD05 FR0000121220 12,472 77.9203 XPAR 16/09/2024 969500AGKR3PRJG4WD05 FR0000121220 11,690 78.0104 CEUX 16/09/2024 969500AGKR3PRJG4WD05 FR0000121220 2,000 77.9691 TQEX 16/09/2024 969500AGKR3PRJG4WD05 FR0000121220 1,774 77.899 AQEU 17/09/2024 969500AGKR3PRJG4WD05 FR0000121220 9,519 78.543 XPAR 17/09/2024 969500AGKR3PRJG4WD05 FR0000121220 5,700 78.5788 CEUX 17/09/2024 969500AGKR3PRJG4WD05 FR0000121220 500 78.6348 TQEX 17/09/2024 969500AGKR3PRJG4WD05 FR0000121220 500 78.6501 AQEU                             Total 44,155 78.1811               Detailed...